We are live on ! Find out more
MP

Mangrove Partners Portfolio holdings

AUM $1.52B
1-Year Est. Return 36.54%
This Fund
S&P 500
This Quarter Est. Return
-27.66%
1 Year Est. Return
+36.54%
3 Year Est. Return
+184.84%
5 Year Est. Return
+166.78%
10 Year Est. Return
+454.52%
AUM
$725M
AUM Growth
+$41.8M
Cap. Flow
+$425M
Cap. Flow %
58.66%
Top 10 Hldgs %
66.05%
Holding
87
New
15
Increased
15
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$292M
2
PCG icon
PG&E
PCG
+$43M
3
SMCI icon
Super Micro Computer
SMCI
+$33.7M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$24.9M
5
TGTX icon
TG Therapeutics
TGTX
+$15.7M

Top Sells

Rank Stock Value
1
NIHD
NII Holdings, Inc. Common Stock
NIHD
+$17.8M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.83M
3
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$5.93M
4
PDCE
PDC Energy, Inc.
PDCE
+$5.77M
5
GYRE icon
Gyre Therapeutics
GYRE
+$4.65M

Sector Composition

Rank Sector Weight
1 Miscellaneous 34.51%
2 Healthcare 19.98%
3 Energy 8.12%
4 Communication Services 7.93%
5 Utilities 6.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
iShares Russell 2000 ETF
IWM
$80.1B
$224M 30.96%
+1,961,000
New +$292M
ECHO
2
EchoStar
ECHO
$27.1B
$52.8M 7.28%
1,651,083
+125,474
+8% +$4.7M
PCG icon
3
PG&E
PCG
$32.6B
$32.8M 4.52%
3,644,586
+3,240,622
+802% +$43M
SMCI icon
4
Super Micro Computer
SMCI
$26.4B
$28.2M 3.9%
+13,269,860
New +$33.7M
AAMI
5
Acadian Asset Management
AAMI
$3.27B
$27.1M 3.74%
4,241,119
+60,446
+1% +$522K
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.94B
$25.8M 3.56%
863,377
-295,239
-25% -$7.83M
CCXI
7
DELISTED
ChemoCentryx, Inc.
CCXI
$23.6M 3.25%
+586,523
New +$24.9M
CIVI
8
DELISTED
Civitas Resources
CIVI
$23.2M 3.2%
2,060,700
– –
SXC icon
9
SunCoke Energy
SXC
$868M
$22.3M 3.08%
5,791,492
+682,400
+13% +$3.46M
DSSI
10
DELISTED
Diamond S Shipping Inc. Common Shares
DSSI
$18.6M 2.57%
1,576,648
+1,004,412
+176% +$11.8M
INSW icon
11
International Seaways
INSW
$5.14B
$18M 2.49%
754,704
-90,271
-11% -$2.05M
ANIP icon
12
ANI Pharmaceuticals
ANIP
$1.61B
$17.4M 2.39%
426,162
+99,384
+30% +$5.29M
GPRE icon
13
Green Plains
GPRE
$1.11B
$17M 2.35%
3,513,739
-81,718
-2% -$882K
CPRX
14
DELISTED
Catalyst Pharmaceutical
CPRX
$16.8M 2.31%
4,355,416
+2,807,100
+181% +$11.5M
AT
15
DELISTED
Atlantic Power Corporation
AT
$16M 2.21%
7,484,189
-270,789
-3% -$616K
CAI
16
DELISTED
CAI International, Inc.
CAI
$14.1M 1.94%
996,897
-104,276
-9% -$2.51M
RNAC icon
17
Cartesian Therapeutics
RNAC
$271M
$13.4M 1.84%
184,962
+9,811
+6% +$947K
TGTX icon
18
TG Therapeutics
TGTX
$8.53B
$12.2M 1.69%
+1,241,706
New +$15.7M
GNK icon
19
Genco Shipping & Trading
GNK
$1.17B
$10.1M 1.4%
1,579,322
-87,500
-5% -$667K
STON
20
DELISTED
StoneMor Inc.
STON
$10.1M 1.39%
9,711,014
-583,818
-6% -$676K
PDCE
21
DELISTED
PDC Energy, Inc.
PDCE
$9.67M 1.33%
1,557,612
-320,408
-17% -$5.77M
IMVT icon
22
Immunovant
IMVT
$8.17B
$8.9M 1.23%
571,942
+471,942
+472% +$7.1M
CUE icon
23
Cue Biopharma
CUE
$218M
$8.53M 1.18%
20,047
– –
PCG icon
24
CALL
PG&E
PCG
$32.6B
$7.91M 1.09%
+880,000
New +$11.7M
BMY.RT
25
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$6.96M 0.96%
+1,830,600
New +$6.03M
1
2 3 4

Similar funds

ACM
Atika Capital Management New York $1.52B AUM 229.41% 1-Year Est. Return
ACM
Adelante Capital Management Alameda, California $1.52B AUM 23.15% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.52B AUM 47.33% 1-Year Est. Return
KCMH
Kontiki Capital Management (HK) Hong Kong $1.52B AUM 10.48% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.52B AUM 3.09% 1-Year Est. Return
WFA
Wellspring Financial Advisors Cleveland, Ohio $1.52B AUM 29.68% 1-Year Est. Return
SC
Styrax Capital New York $1.52B AUM 57.44% 1-Year Est. Return

Mangrove Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Mangrove Partners held 87 positions worth $725M, up 6.1% from $683M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Mangrove Partners deployed $425M of net new capital in Q1 2020, opening 15 new positions and adding to 15 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 1,961,000 shares worth $224M.

By sector, the portfolio is most concentrated in Miscellaneous at 35% of assets, up from 4.4% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $7.83M trimmed.

  • Mangrove Partners's largest Q1 2020 buy was iShares Russell 2000 ETF: 1,961,000 shares worth $224M.
  • Mangrove Partners added most to PG&E in Q1 2020, an estimated $43M increase.
  • Mangrove Partners's biggest Q1 2020 reduction was Iovance Biotherapeutics, cutting an estimated $7.83M.
  • Mangrove Partners fully exited NII Holdings, Inc. Common Stock in Q1 2020, selling an estimated $17.8M.
  • Mangrove Partners's ten largest holdings make up 66% of its $725M portfolio in Q1 2020.
  • Mangrove Partners opened 15 new positions and closed 10 in Q1 2020.
  • Mangrove Partners's portfolio value rose 6.1% quarter-over-quarter to $725M.

Based on Mangrove Partners's 13F filing for Q1 2020, filed 15 May 2020.